Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments (2017 - 2025)

Arcus Biosciences has reported Short-term Investments over the past 9 years, most recently at $759.0 million for Q4 2025.

  • Quarterly results put Short-term Investments at $759.0 million for Q4 2025, down 8.33% from a year ago — trailing twelve months through Dec 2025 was $759.0 million (down 8.33% YoY), and the annual figure for FY2025 was $759.0 million, down 8.33%.
  • Short-term Investments for Q4 2025 was $759.0 million at Arcus Biosciences, up from $593.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for RCUS hit a ceiling of $900.1 million in Q2 2022 and a floor of $345.2 million in Q3 2021.
  • Median Short-term Investments over the past 5 years was $708.0 million (2023), compared with a mean of $677.7 million.
  • Peak annual rise in Short-term Investments hit 382.29% in 2021, while the deepest fall reached 38.42% in 2021.
  • Arcus Biosciences' Short-term Investments stood at $351.0 million in 2021, then skyrocketed by 128.77% to $803.0 million in 2022, then fell by 21.3% to $632.0 million in 2023, then skyrocketed by 31.01% to $828.0 million in 2024, then decreased by 8.33% to $759.0 million in 2025.
  • The last three reported values for Short-term Investments were $759.0 million (Q4 2025), $593.0 million (Q3 2025), and $663.0 million (Q2 2025) per Business Quant data.